On Friday, Following U.S. Stocks were among the “Top Gainers”: HollyFrontier (NYSE:HFC), Applied Materials, (NASDAQ:AMAT), WPX Energy (NYSE:WPX), Hemispherx BioPharma, (NYSEMKT:HEB)
HollyFrontier Corp (NYSE:HFC) disclosed a fourth quarter net loss attributable to HollyFrontier stockholders of $222.2 million or $(1.13) for each diluted share for the quarter ended December 31, 2014, compared to net income of $62.9 million or $0.31 per diluted share for the quarter ended December 31, 2013. Included in the current quarter results were a non-cash lower of cost or market inventory valuation adjustment that generated an after-tax charge of $244.0 million or $1.25 per share.
HollyFrontier Corp (NYSE:HFC) inclined 2.01%, and closed at $39.12. The company has the market capitalization of $7.65 billion. In the last trading session 4.05M shares changed hands as compared to its average volume of 3.56M. The beta value of the stock is 1.39. On the other hand the stock’s volatility for the week is 3.70%, and for the month is 3.48%. The stock price to book value is $1.38; however price to sale value is $0.39. Analyst’s mean recommendation regarding this stock is 2.80. (Where 1=Buy, 5=Sale).
HollyFrontier Corp (HFC), works as an independent petroleum refiner in the United States. The corporation works in two segments, Refining and HEP. It produces high-value refined products, such as gasoline, diesel fuel, jet fuel, specialty lubricant products, liquid petroleum gas, fuel oil, and specialty and modified asphalt.
Applied Materials, Inc. (NASDAQ:AMAT) promulgated that its Board of Directors has approved a quarterly cash dividend of $0.10 per share due on the corporation`s ordinary stock. The dividend is due on June 11, 2015 to stockholders of record as of May 21, 2015.
Applied Materials, Inc. (NASDAQ:AMAT) raised 1.98%, and closed at $24.24. The stock has price to sale value of 3.22, however, price to book value is 3.68. With recent incline, the year-to-date (YTD) performance reflected a -3.89% decline below last year. During the past month the stock gained 0.5%, bringing three-month performance to 3.63% and six-month performance to 9.93%. The mean recommendation of analysts for this stock is 2.00. (Where 1=Buy, 5=Sale).
Applied Materials, Inc. (AMAT) offers manufacturing equipment, services, and software to the semiconductor, flat panel display, solar photovoltaic (PV), and related industries international.
WPX Energy Inc (NYSE:WPX) Chief Executive Officer Rick Muncrief is programmed to speak at the 43rd yearly Scotia Howard Weil energy symposium on Monday, March 23, at 2:30 p.m. Central.
WPX Energy Inc (NYSE:WPX) enhanced 1.96%, and closed at $10.91. The company holds the market capitalization of 2.22 billion. For the trailing twelve months, the stock’s return on equity value remains 4.40%, while return on assets value is 2.20%, in response to its return on investment value of 3.80%. Its 20-day moving average decreased -5.27%, below 50-day moving average of -5.64%, below 200-day moving average of -39.84% from the latest market price of $10.91. The mean recommendation of analysts for this stock is 2.20. (Where 1=Buy, 5=Sale).
WPX Energy Inc (WPX) an independent natural gas and oil exploration and production corporation holds in the exploitation and development of unconventional properties in the United States.
Hemispherx BioPharma, Inc (NYSEMKT:HEB) promulgated that it has executed a contract with Emerge Health Pty Ltd. (“Emerge”) to seek approval of Ampligen, an experimental immunotherapeutic, for Chronic Fatigue Syndrome in Australia and New Zealand and to commence distribution of Ampligen in both countries on a named-patient basis, where deemed appropriate.
Hemispherx BioPharma, Inc (NYSEMKT:HEB)’s shares picked up 1.52%, and closed at $0.235. The stock volatility for the week is 6.85%, while for the month remained 7.19%. The company holds consensus target price of $3.00.
If we consider EPS growth of the company, then we will notice the following observations:
The company showed -0.09 diluted EPS growth for trailing twelve months. However, YTD EPS growth remained 16.70 and Annual EPS growth for the past 5 years is considered as 9.00%.
The mean recommendation of analysts for this stock is 2.00. (Where 1=Buy, 5=Sale).
Hemispherx BioPharma, Inc (HEB) a specialty pharmaceutical corporation, is involved in the medical development of new drug therapies based on natural immune system enhancing technologies for the cure of viral and immune based chronic disorders in the United States.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The data demonstrated in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
